Pilot study of pharmacological treatment for frontotemporal dementia: effect of Yokukansan on behavioral symptoms.
The aim of the present study was to investigate the efficacy of Yokukansan in improving behavioral symptoms of frontotemporal dementia. This study was a prospective, open-label trial of daily Yokukansan for 4 weeks in 20 frontotemporal dementia patients. Yokukansan treatment was found to significantly improve scores for the Neuropsychiatric Inventory and the Stereotypy Rating Inventory. No adverse effects or significant changes in physical findings and laboratory data occurred except for hypokalemia in two cases. The results indicate that Yokukansan can alleviate the behavioral symptoms of frontotemporal dementia. (The clinical trial registration number is UMIN000002704).
Kimura
Takemi
T
Division of Clinical Research, National Hospital Organization Kikuchi Hospital, 208 Fukuhara, Koshi, Kumamoto 861-1116, Japan. tkimura@kikuti.hosp.go.jp
Hayashida
Hideki
H
Furukawa
Hitomi
H
Takamatsu
Junichi
J
D000368:Aged; D000369:Aged, 80 and over; D014150:Antipsychotic Agents / Q000627:therapeutic use; D004365:Drugs, Chinese Herbal / Q000627:therapeutic use*; D005260:Female; D057180:Frontotemporal Dementia / Q000188:drug therapy*; D006801:Humans; D008297:Male; D009483:Neuropsychological Tests; D018579:Patient Selection; D010865:Pilot Projects; D011446:Prospective Studies
D014150:Antipsychotic Agents; D004365:Drugs, Chinese Herbal; C524644:Yi-Gan San